Control of Slc7a5 sensitivity by the voltage-sensing domain of Kv1 channels

  1. Shawn M Lamothe
  2. Nazlee Sharmin
  3. Grace Silver
  4. Motoyasu Satou
  5. Yubin Hao
  6. Toru Tateno
  7. Victoria A Baronas
  8. Harley Takatsuna Kurata  Is a corresponding author
  1. University of Alberta, Canada
  2. Dokkyo Medical University School of Medicine, Japan

Abstract

Many voltage-dependent ion channels are regulated by accessory proteins. We recently reported powerful regulation of Kv1.2 potassium channels by the amino acid transporter Slc7a5. In this study, we report that Kv1.1 channels are also regulated by Slc7a5, albeit with different functional outcomes. In heterologous expression systems, Kv1.1 exhibits prominent current enhancement ('disinhibition') with holding potentials more negative than -120 mV. Knockdown of endogenous Slc7a5 leads to larger Kv1.1 currents, and strongly attenuates the disinhibition effect, suggesting that Slc7a5 regulation of Kv1.1 involves channel inhibition that can be reversed by supraphysiological hyperpolarizing voltages. We investigated chimeric combinations of Kv1.1 and Kv1.2, demonstrating that exchange of the voltage-sensing domain controls the sensitivity and response to Slc7a5, and localize a specific position in S1 with prominent effects on Slc7a5 sensitivity. Overall, our study highlights multiple Slc7a5-sensitive Kv1 subunits, and identifies the voltage-sensing domain as a determinant of Slc7a5 modulation of Kv1 channels.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for all figures.

Article and author information

Author details

  1. Shawn M Lamothe

    Pharmacology, University of Alberta, Edmonton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  2. Nazlee Sharmin

    Dentistry, University of Alberta, Edmonton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Grace Silver

    Pharmacology, University of Alberta, Edmonton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  4. Motoyasu Satou

    Biochemistry, Dokkyo Medical University School of Medicine, Soka, Japan
    Competing interests
    The authors declare that no competing interests exist.
  5. Yubin Hao

    Pharmacology, University of Alberta, Edmonton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  6. Toru Tateno

    Medicine, University of Alberta, Edmonton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  7. Victoria A Baronas

    Pharmacology, University of Alberta, Edmonton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  8. Harley Takatsuna Kurata

    Pharmacology/Alberta Diabetes Institute, University of Alberta, Edmonton, Canada
    For correspondence
    kurata@ualberta.ca
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4357-4189

Funding

Canadian Institutes of Health Research (Project Grant)

  • Harley Takatsuna Kurata

Canadian Institutes of Health Research (Vanier Studentship)

  • Victoria A Baronas

University of Alberta (Rowland and Muriel Haryett fellowship)

  • Shawn M Lamothe

Natural Sciences and Engineering Research Council of Canada (USRA)

  • Grace Silver

Canadian Institutes of Health Research (Early Career Investigator)

  • Harley Takatsuna Kurata

Alberta Diabetes Institute (Salary support)

  • Harley Takatsuna Kurata

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Lamothe et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,162
    views
  • 148
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shawn M Lamothe
  2. Nazlee Sharmin
  3. Grace Silver
  4. Motoyasu Satou
  5. Yubin Hao
  6. Toru Tateno
  7. Victoria A Baronas
  8. Harley Takatsuna Kurata
(2020)
Control of Slc7a5 sensitivity by the voltage-sensing domain of Kv1 channels
eLife 9:e54916.
https://doi.org/10.7554/eLife.54916

Share this article

https://doi.org/10.7554/eLife.54916

Further reading

    1. Medicine
    2. Neuroscience
    LeYuan Gu, WeiHui Shao ... HongHai Zhang
    Research Article

    The advent of midazolam holds profound implications for modern clinical practice. The hypnotic and sedative effects of midazolam afford it broad clinical applicability. However, the specific mechanisms underlying the modulation of altered consciousness by midazolam remain elusive. Herein, using pharmacology, optogenetics, chemogenetics, fiber photometry, and gene knockdown, this in vivo research revealed the role of locus coeruleus (LC)-ventrolateral preoptic nucleus noradrenergic neural circuit in regulating midazolam-induced altered consciousness. This effect was mediated by α1 adrenergic receptors. Moreover, gamma-aminobutyric acid receptor type A (GABAA-R) represents a mechanistically crucial binding site in the LC for midazolam. These findings will provide novel insights into the neural circuit mechanisms underlying the recovery of consciousness after midazolam administration and will help guide the timing of clinical dosing and propose effective intervention targets for timely recovery from midazolam-induced loss of consciousness.

    1. Neuroscience
    Ana Maria Ichim, Harald Barzan ... Raul Cristian Muresan
    Review Article

    Gamma oscillations in brain activity (30–150 Hz) have been studied for over 80 years. Although in the past three decades significant progress has been made to try to understand their functional role, a definitive answer regarding their causal implication in perception, cognition, and behavior still lies ahead of us. Here, we first review the basic neural mechanisms that give rise to gamma oscillations and then focus on two main pillars of exploration. The first pillar examines the major theories regarding their functional role in information processing in the brain, also highlighting critical viewpoints. The second pillar reviews a novel research direction that proposes a therapeutic role for gamma oscillations, namely the gamma entrainment using sensory stimulation (GENUS). We extensively discuss both the positive findings and the issues regarding reproducibility of GENUS. Going beyond the functional and therapeutic role of gamma, we propose a third pillar of exploration, where gamma, generated endogenously by cortical circuits, is essential for maintenance of healthy circuit function. We propose that four classes of interneurons, namely those expressing parvalbumin (PV), vasointestinal peptide (VIP), somatostatin (SST), and nitric oxide synthase (NOS) take advantage of endogenous gamma to perform active vasomotor control that maintains homeostasis in the neuronal tissue. According to this hypothesis, which we call GAMER (GAmma MEdiated ciRcuit maintenance), gamma oscillations act as a ‘servicing’ rhythm that enables efficient translation of neural activity into vascular responses that are essential for optimal neurometabolic processes. GAMER is an extension of GENUS, where endogenous rather than entrained gamma plays a fundamental role. Finally, we propose several critical experiments to test the GAMER hypothesis.